Hepion Pharmaceuticals (HEPA) News Today $0.07 -0.01 (-17.14%) As of 08/29/2025 03:52 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Hepion Pharmaceuticals CFO John Brancaccio resigns effective MondayJuly 1, 2025 | investing.comHepion Pharmaceuticals Successfully Completes Application to the OTCQBJune 25, 2025 | globenewswire.comHEPA Hepion Pharmaceuticals, Inc.CJune 22, 2025 | seekingalpha.comHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEOJune 17, 2025 | nasdaq.comHepion Pharmaceuticals reports annual meeting resultsJune 14, 2025 | investing.comHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 13, 2025 | finanznachrichten.deHepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'May 12, 2025 | msn.comHepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 12, 2025 | globenewswire.comHepion Pharmaceuticals Enters Binding LOI with New Day Diagnostics for In-Licensing of CE-Marked Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Partners With New Day Diagnostics To Commercialize Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCCMay 7, 2025 | globenewswire.comHepion Pharmaceuticals faces potential Nasdaq delistingMarch 22, 2025 | investing.comHepion Pharmaceuticals enacts reverse stock splitMarch 21, 2025 | investing.comHepion Pharmaceuticals trading halted, news pendingMarch 18, 2025 | markets.businessinsider.comHepion Pharmaceuticals announces 1-for-50 reverse stock splitMarch 14, 2025 | markets.businessinsider.comHepion Pharmaceuticals Announces Reverse Stock SplitMarch 14, 2025 | globenewswire.comHepion Pharmaceuticals announces $9M public offeringJanuary 22, 2025 | markets.businessinsider.comHepion Pharmaceuticals Announces $9.0 Million Public OfferingJanuary 22, 2025 | markets.businessinsider.comHepion Pharmaceuticals files to sell common stock, warrants, no amount givenDecember 26, 2024 | markets.businessinsider.comHepion Pharmaceuticals Terminates Merger with Pharma Two BDecember 11, 2024 | markets.businessinsider.comHepion Pharmaceuticals terminates merger agreement with Pharma Two BDecember 11, 2024 | markets.businessinsider.comHepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.December 11, 2024 | globenewswire.comPharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study GroupDecember 5, 2024 | markets.businessinsider.comPharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study GroupDecember 5, 2024 | globenewswire.comHepion Pharmaceuticals’ shareholder letter urging support for Pharma Two B dealDecember 2, 2024 | markets.businessinsider.comHepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two BDecember 2, 2024 | globenewswire.comHepion, Pharma Two B announce effectiveness of registration statement for mergerNovember 12, 2024 | markets.businessinsider.comPharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed MergerNovember 11, 2024 | tmcnet.comHepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comPharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed MergerSeptember 4, 2024 | globenewswire.com336.SG,0P00015I0V,0 (336.SG)August 14, 2024 | finance.yahoo.comHepatitis B Virus Infection Pipeline Insight Report 2024: Therapeutic Assessment of 80+ Companies and 90+ DrugsAugust 13, 2024 | uk.finance.yahoo.comHepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the DomainAugust 1, 2024 | finance.yahoo.comOligonucleotide Therapy Market to Reach USD 19.92 Billion by 2031 | InsightAce AnalyticJuly 23, 2024 | theglobeandmail.comHepion Pharmaceuticals Inc. Pfd.July 23, 2024 | wsj.comFatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug DeveloperJuly 22, 2024 | benzinga.comPharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private PlacementJuly 22, 2024 | finance.yahoo.comFatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug DeveloperJuly 22, 2024 | benzinga.comHEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024May 21, 2024 | investorplace.comU.S. Lags Behind Other Countries in Hepatitis-C TreatmentApril 28, 2024 | nytimes.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | finance.yahoo.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 22, 2024 | investorplace.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 21, 2024 | stockhouse.comHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource ConstraintsApril 19, 2024 | marketwatch.comHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down TrialApril 19, 2024 | marketwatch.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialApril 19, 2024 | finance.yahoo.comHepion Pharmaceuticals (Nasdaq:HEPA) HeadlineTrading was temporarily halted for "HEPA" at 04:04 PM with a stated reason of "News pending."...April 19, 2024 | marketbeat.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialApril 19, 2024 | globenewswire.com Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEPA Media Mentions By Week HEPA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HEPA News Sentiment▼0.001.11▲Average Medical News Sentiment HEPA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HEPA Articles This Week▼00▲HEPA Articles Average Week Get the Latest News and Ratings for HEPA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Hepion Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ATXI News AKAN News SCNI News EVFM News ZVSA News PTPI News TNFA News BPTH News ORGS News WINT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HEPA) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts